Estrogenic components for use in the treatment of neurological disorders
The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol, in neurological disorders, such as neonatal hypoxic-ischemic encephalopathy (HIE).
1. A method of treatment of hypoxic-ischemic encephalopathy (HIE) in a subject in need thereof, comprising administering to the subject an amount of 1,3,5(10)-estratrien-3,15a,16a,17β-tetrol effective for said treatment.
2. The method of claim 1 , wherein the treatment of the HIE is therapeutic.
3. The method according to claim 1 , wherein the HIE is neonatal HIE.
4. The method according to claim 1 wherein the 1,3,5(10)-estratrien-3,15a,16a,17β-tetrol is administered within 12 hours after said HIE.
5. The method according to claim 4 , wherein the 1,3,5(10)-estratrien-3,15a,16a,17β-tetrol is administered within 6 hours after said HIE.
6. The method of claim 3 , wherein the 1,3,5(10)-estratrien-3,15a,16a,17β-tetrol is administered in combination with reducing body temperature to 33° C. to 34° C.
7. The method according to claim 1 , wherein the 1,3,5(10)-estratrien-3,15a,16a,17β-tetrol is administered in a range from about 1 μg/kg to about 250 mg/kg body weight per day.
8. The method according to claim 7 , wherein the 1,3,5(10)-estratrien-3,15a,16a,17β-tetrol is administered in doses of from about 0.05 mg/kg to about 100 mg/kg body weight for a period of a plurality of days until desired suppression of symptoms occurs.
9. The method of claim 8 , wherein the doses are administered as a single daily dose, divided over one or more daily doses, or every week or longer.
10. The method of claim 7 , wherein the 1,3,5(10)-estratrien-3,15a,16a,17β-tetrol is administered essentially continuously.